Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients

Seminars in Arthritis and Rheumatism

Volumn 45, Issue 3, 2015, Pages 361-368

  Riancho Zarrabeitia, Leyre ^a   Calvo Río, Vanesa ^a   Blanco, Ricardo ^a   Mesquida, Marina ^b   Adan, Alfredo M ^b   Herreras, José M ^c   Aparicio, Ángel ^d   Peiteado Lopez, Diana ^e   Cordero Coma, Miguel ^f   García Serrano, José Luis ^g   Ortego Centeno, Norberto ^g   Maíz, Olga ^h   Blanco, Ana ^h   Sánchez Bursón, Juan ⁱ   González Suárez, Senén ^j   Fonollosa, Alejandro ^k   Santos Gómez, Montserrat ^a   González Vela, Carmen ^a   Loricera, Javier ^a   Pina, Trinitario ^a   González Gay, Miguel A ^a   more..

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^d Hospital Univ de Toledo   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f UNIVERSITY OF LEÓN   (Spain)

^g HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^h HOSPITAL DONOSTIA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^j HOSPITAL DE CABUEÑES   (Spain)

^k HOSPITAL DE CRUCES   (Spain)

more..

Author keywords

Biologic therapy; Sarcoidosis; Uveitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; GOLIMUMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; CYCLOSPORIN; TUMOR NECROSIS FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; HUMAN; INFUSION RELATED REACTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; LYMPHADENOPATHY; MACULAR THICKNESS; MALE; OPEN STUDY; PRIORITY JOURNAL; PSORIASIS; RETROSPECTIVE STUDY; SARCOIDOSIS; UVEITIS; VISUAL ACUITY; VITRITIS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; MULTICENTER STUDY; RETREATMENT; TREATMENT OUTCOME; YOUNG ADULT;

ADALIMUMAB; ADOLESCENT; ADULT; AGED; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLIXIMAB; MALE; METHOTREXATE; MIDDLE AGED; PREDNISONE; RETREATMENT; RETROSPECTIVE STUDIES; SARCOIDOSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; YOUNG ADULT;

EID: 84955642888     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2015.05.010     Document Type: Article

References (62)

1. Hamzeh N. Sarcoidosis. Med Clin North Am 2011, 95:1223-1234.
2. Culver D.A. Sarcoidosis. Immunol Allergy Clin North Am 2012, 32:487-511.
3. Valeyre D., Prasse A., Nunes H., Uzunhan Y., Brillet P.Y., Muller-Quernheim J. Sarcoidosis. Lancet 2014, 383:1155-1167.
4. Phillips Y.L., Eggenberger E.R. Neuro-ophthalmic sarcoidosis. Curr Opin Ophthalmol 2010, 21:423-429.
5. Bonfioli A.A., Orefice F. Sarcoidosis. Semin Ophthalmol 2005, 20:177-182.
6. Umur K.A., Tayfun B., Oguzhan O. Different ophthalmologic manifestations of sarcoidosis. Curr Opin Ophthalmol 2012, 23:477-484.
7. Iannuzzi M.C., Rybicki B.A., Teirstein A.S. Sarcoidosis. N Engl J Med 2007, 357:2153-2165.
8. Riancho-Zarrabeitia L., Delgado-Alvarado M., Riancho J., Oterino A., Sedano M.J., Rueda-Gotor J., et al. Anti-TNF-alpha therapy in the management of severe neurosarcoidosis: a report of five cases from a single centre and literature review. Clin Exp Rheumatol 2014, 32:275-284.
9. Lazarus A. Sarcoidosis: epidemiology, etiology, pathogenesis, and genetics. Dis Mon 2009, 55:649-660.
10. Holmes J., Lazarus A. Sarcoidosis: extrathoracic manifestations. Dis Mon 2009, 55:675-692.
11. Baughman R.P., Costabel U., du Bois R.M. Treatment of sarcoidosis. Clin Chest Med 2008, 29:533-548.
12. Pereira J., Anderson N.E., McAuley D., Bergin P., Kilfoyle D., Fink J. Medically refractory neurosarcoidosis treated with infliximab. Intern Med J 2011, 41:354-357.
13. Cottin V. Update on bioagent therapy in sarcoidosis. F1000 Med Rep 2010, 2.
14. Judson M.A., Baughman R.P., Costabel U., Flavin S., Lo K.H., Kavuru M.S., et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008, 31:1189-1196.
15. Doty J.D., Mazur J.E., Judson M.A. Treatment of sarcoidosis with infliximab. Chest 2005, 127:1064-1071.
16. Sodhi M., Pearson K., White E.S., Culver D.A. Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis. Respir Med 2009, 103:268-273.
17. Herbort C.P., Rao N.A., Mochizuki M. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop on Ocular Sarcoidosis (IWOS). Ocul Immunol Inflamm 2009, 17:160-169.
18. Deschenes J., Murray P.I., Rao N.A., Nussenblatt R.B. International Uveitis Study Group IUSG: clinical classification of uveitis. Ocul Immunol Inflamm 2008, 16:1-2.
19. Jabs D.A., Nussenblatt R.B., Rosenbaum J.T. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005, 140:509-516.
20. Nussenblatt R.B., Palestine A.G., Chan C.C., Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985, 92:467-471.
21. Nussenblatt R.B., Peterson J.S., Foster C.S., Rao N.A., See R.F., Letko E., et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 2005, 112:764-770.
22. Baughman R.P., Teirstein A.S., Judson M.A., Rossman M.D., Yeager H., Bresnitz E.A., et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001, 164:1885-1889.
23. Rose A.S., Tielker M.A., Knox K.S. Hepatic, ocular, and cutaneous sarcoidosis. Clin Chest Med 2008, 29:509-524. ix.
24. Jabs D.A., Johns C.J. Ocular involvement in chronic sarcoidosis. Am J Ophthalmol 1986, 102:297-301.
25. Pan J., Kapur M., McCallum R. Noninfectious immune-mediated uveitis and ocular inflammation. Curr Allergy Asthma Rep 2014, 14:409.
26. Bejerano C., Blanco R., Gonzalez-Vela C., Aguero R., Carril J.M., Gonzalez-Gay M.A. Refractory polymyalgia rheumatica as presenting manifestation of large-vessel vasculitis associated to sarcoidosis. Successful response to adalimumab. Clin Exp Rheumatol 2012, 30(1 Suppl 70):S94-S97.
27. Callejas-Rubio J.L., Ortego-Centeno N., Lopez-Perez L., Benticuaga M.N. Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol 2006, 25:596-597.
28. Kamphuis L.S., Lam-Tse W.K., Dik W.A., van Daele P.L., van Biezen P., Kwekkeboom D.J., et al. Efficacy of adalimumab in chronically active and symptomatic patients with sarcoidosis. Am J Respir Crit Care Med 2011, 184:1214-1216.
29. Saleh S., Ghodsian S., Yakimova V., Henderson J., Sharma O.P. Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med 2006, 100:2053-2059.
30. Benitez-Del-Castillo J.M., Martinez-de-la-Casa J.M., Pato-Cour E., Mendez-Fernandez R., Lopez-Abad C., Matilla M., et al. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye 2005, 19:841-845.
31. Lindstedt E.W., Baarsma G.S., Kuijpers R.W., van Hagen P.M. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005, 89:533-536.
32. Suhler E.B., Smith J.R., Wertheim M.S., Lauer A.K., Kurz D.E., Pickard T.D., et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 2005, 123:903-912.
33. Suhler E.B., Smith J.R., Giles T.R., Lauer A.K., Wertheim M.S., Kurz D.E., et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol 2009, 127:819-822.
34. Baughman R.P., Bradley D.A., Lower E.E. Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther 2005, 43:7-11.
35. Cruz B.A., Reis D.D., Araujo C.A. Refractory retinal vasculitis due to sarcoidosis successfully treated with infliximab. Rheumatol Int 2007, 27:1181-1183.
36. Suhler E.B., Lowder C.Y., Goldstein D.A., Giles T., Lauer A.K., Kurz P.A., et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol 2013, 97:481-486.
37. Diaz-Llopis M., Salom D., Garcia-de-Vicuna C., Cordero-Coma M., Ortega G., Ortego N., et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 2012, 119:1575-1581.
38. Erckens R.J., Mostard R.L., Wijnen P.A., Schouten J.S., Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 2012, 250:713-720.
39. Sanchez-Cano D., Callejas-Rubio J.L., Ruiz-Villaverde R., Rios-Fernandez R., Ortego-Centeno N. Off-label uses of anti-TNF therapy in three frequent disorders: Behcet's disease, sarcoidosis, and noninfectious uveitis. Mediators Inflamm 2013, 2013:286857.
40. Theodossiadis P.G., Markomichelakis N.N., Sfikakis P.P. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 2007, 27:399-413.
41. Fleisher L.N., Ferrell J.B., McGahan M.C. Ocular inflammatory effects of intravitreally injected tumor necrosis factor-alpha and endotoxin. Inflammation 1990, 14:325-335.
42. Rosenbaum J.T., Howes E.L., Rubin R.M., Samples J.R. Ocular inflammatory effects of intravitreally-injected tumor necrosis factor. Am J Pathol 1988, 133:47-53.
43. Baughman R.P., Lower E.E., Bradley D.A., Raymond L.A., Kaufman A. Etanercept for refractory ocular sarcoidosis: results of a double-blind randomized trial. Chest 2005, 128:1062-1147.
44. Smith J.A., Thompson D.J., Whitcup S.M., Suhler E., Clarke G., Smith S., et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005, 53:18-23.
45. Pasadhika S., Rosenbaum J.T. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics 2014, 8:67-81.
46. Miserocchi E., Modorati G., Pontikaki I., Meroni P.L., Gerloni V. Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm 2014, 22:90-95.
47. Maiz Alonso O., Blanco Esteban A.C., Egües Dubuc C.A., Martinez Zabalegui D. Effectiveness of certolizumab pegol in chronic anterior uveitis associated to Crohn's disease and ankylosing spondylitis. Reumatol Clin 2015, 11:189-190.
48. Llorenç V., Mesquida M., Sainz de la Maza M., Blanco R., Calvo V., Maíz O., et al. Certolizumab Pegol a New Anti-TNF-α in the Armamentarium against Ocular Inflammation. Ocul Immunol Inflamm 2014, 17:1-6.
49. He Y., Jia S.B., Zhang W., Shi J.M. New options for uveitis treatment. Int J Ophthalmol 2013, 6:702-707.
50. Sobrin L., Kim E.C., Christen W., Papadaki T., Letko E., Foster C.S. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007, 125:895-900.
51. Dhingra N., Morgan J., Dick A.D. Switching biologic agents for uveitis. Eye 2009, 23:1868-1870.
52. Olivieri I., Leccese P., D'Angelo S., Padula A., Nigro A., Palazzi C., et al. Efficacy of adalimumab in patients with Behcet's disease unsuccessfully treated with infliximab. Clin Exp Rheumatol 2011, 29(4 Suppl 67):S54-S57.
53. Baughman R.P., Drent M., Kavuru M., Judson M.A., Costabel U., du B.R., et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006, 174:795-802.
54. Baughman R.P., Lower E.E., Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis 2008, 25:76-89.
55. Adan A., Hernandez V., Ortiz S., Molina J.J., Pelegrin L., Espinosa G., et al. Effects of infliximab in the treatment of refractory posterior uveitis of Behcet's disease after withdrawal of infusions. Int Ophthalmol 2010, 30:577-581.
56. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. J Am Med Assoc 2006, 295:2275-2285.
57. Lim L.L., Fraunfelder F.W., Rosenbaum J.T. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007, 56:3248-3252.
58. Wendling D., Paccou J., Berthelot J.M., Flipo R.M., Guillaume-Czitrom S., Prati C., et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 2011, 41:503-510.
59. Hashkes P.J., Shajrawi I. Sarcoid-related uveitis occurring during etanercept therapy. Clin Exp Rheumatol 2003, 21:645-646.
60. Tong D., Manolios N., Howe G., Spencer D. New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication. Intern Med J 2012, 42:89-94.
61. Gonzalez-Lopez M.A., Blanco R., Gonzalez-Vela M.C., Fernandez-Llaca H., Rodriguez-Valverde V. Development of sarcoidosis during etanercept therapy. Arthritis Rheum 2006, 55:817-820.
62. Dragnev D., Barr D., Kulshrestha M., Shanmugalingam S. Sarcoid panuveitis associated with etanercept treatment, resolving with adalimumab. BMJ Case Rep 2013, 2013.